PLRX — PLIANT THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1746473 ·
Last close
$1.08
Market Cap
$66.88M
52W High
$1.95
52W Low
$1.02
ADV30
426,523
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -23,862,000 | -22,371,000 | 189,881,000 | 24,883,000 | 42,955,000 |
| Mar 2026 | 0 | — | -21,772,000 | -20,040,000 | 202,596,000 | 22,190,000 | 37,430,000 |
| Dec 2025 | 0 | — | -23,577,000 | -23,577,000 | 225,228,000 | 45,445,000 | 44,023,000 |
| Sep 2025 | 0 | — | -28,269,000 | -26,301,000 | 276,600,000 | 93,732,000 | 76,294,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-98,701,000
Investing CF
$61,076,000
Financing CF
$-32,121,000
CapEx
$-583,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.84
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-879,436,000
Inventory
—
Receivables
$914,000
ST Investments
$148,702,000
EBIT TTM
$-111,458,000
Pretax Income TTM
$-113,218,000
Interest Exp TTM
$1,760,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -156,373,000 | -149,344,000 | 225,228,000 | 44,023,000 | 181,205,000 | -128,336,000 |
| Dec 2024 | 0 | -228,365,000 | -210,304,000 | 396,949,000 | 92,868,000 | 304,081,000 | -155,503,000 |
| Dec 2023 | 1,580,000 | -184,145,000 | -161,336,000 | 512,154,000 | 38,578,000 | 473,576,000 | -116,361,000 |
| Dec 2022 | 9,685,000 | -127,200,000 | -123,321,000 | 350,613,000 | 37,271,000 | 313,342,000 | -94,631,000 |
TTM Snapshot
Revenues TTM
$-240,416,000
NetIncome TTM
$-186,031,000
OpCashFlow TTM
$0
Assets (Latest)
$225,228,000
Forward EPS
$-1.28
Max Pain — expiry 2026-10-16
max pain strike: $1.00 · spot: $1.08 · call oi: 217 · put oi: 2,236
Expected Move to 2026-10-16:
±$0.38
(35.19%) —
implied range
$0.70 –
$1.46
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | $66.85M | $10.94 | — |
| ATHE | ALTERITY THERAPEUTICS LTD | $66.82M | $3.67 | — |
| XBIT | XBiotech Inc. | $66.16M | $2.17 | — |
| TENX | TENAX THERAPEUTICS, INC. | $67.74M | $1.81 | — |
| CNTB | Connect Biopharma Holdings Ltd | $68.01M | $1.08 | — |
News headlines (Yahoo Finance, 1h cache)
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
2026-08-18 12:30 · Yahoo
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-08-11 20:05 · Yahoo
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
2026-07-13 12:30 · Yahoo
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
2026-05-06 12:30 · Yahoo
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
2026-04-30 12:30 · Yahoo
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
2026-04-18 17:31 · Yahoo
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
2026-05-11 20:05 · Yahoo
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
2026-03-18 13:00 · Yahoo
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
2026-03-11 20:05 · Yahoo
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference
2026-03-01 15:39 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.